Acute pericarditis as an organic manifestation of the acute infection Chlamydia pneumoniae

Česká verzia

Authors: M. Rýzlová; P. Gregor
Authors place of work: III. interní-kardiologická klinika 3. lékařské fakulty UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Petr Widimský, DrSc., FESC
Published in the journal: Vnitř Lék 2008; 54(9): 866-870
Category: Case Report

Summary

The article presents the case of a 52-year-old patient who was treated in our clinic for very serious acute Chlamydia pericarditis (a Chlamydia pneumonia infection) with a large pericardial exudate. The clinical progression was that of an acute systematic illness. The article describes the differential diagnostic algorithm used during hospitalisation and the corresponding treatments provided. Similar cases are very rarely described in the literature. The discussion includes an analysis of the possible organic manifestations of acute and chronic Chlamydia pneumoniae infections. This bacterium most frequently attacks the respiratory tract but in humans may also cause separate organic complications such as effects on joints, the lungs, the CNS and the heart. The medicine of choice is always long‑term antibiotic therapy (macrolides, fluoroquinolones and tetracyclines).

Keywords:
Chlamydia pneumoniae – pericarditis – organic manifestations

Zdroje

1. Gibbs ChR, Watson RD, Singh SP et al. Management of Pericardial Effusion by Drainage: Survey of 10 Years’ Experience in a City Centre General Hospital Serving a Multiracial Population. Postgrad Med J 2000; 76: 809–813.

2. Tanenbaum T, Heusch A, Henrich B etal. Acute hemorrhagic pericarditis in a child with pneumonia due to Chlamydophila pneumoniae. J Clin Microbiol 2005; 43: 520–522.

3. Zver S, Kozelj M, Cernelc P. Chlamydia pneumoniae pneumonia with acute hemor-rhagic pericarditis in patient with acute leukemia. Haematologica 1997; 82: 254.

4. Villareal Ch, Whittum-Hudson J, Hudson A. Persistent chlamydiae and chronic arthritis. Arthritis Res 2002; 4: 5–9.

5. Hannu T, Puolakkainen M, Leirisalo-Repo M. Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford) 1999; 38: 411–414.

6. Schumacher HR, Gérard HC, Arayssi TK et al. Lower prevalence of Chlamydia pneumoniae DNA compared with Chlamydia trachomatis DNA in synovial tissue of arthritis patients. Arthritis Rheum 1999; 42: 1889–1893.

7. Melby KK, Kvien KT, Glennas A et al. Chlamydia pneumoniae as a trigger of reactive arthritis. Scand J Infect Dis 1999; 31: 327–328.

8. Braun J, Laitko S, Treharne J et al. Chlamydia pneumoniae – a new causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis 1994; 53: 100–105.

9. Fendler C, Laitko S, Sorensen H et al. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis 2001; 60: 337–343.

10. Laurila AL, Von Hertzen L, Saikku P. Chlamydia pneumoniae and chronic lung diseases. Scand J Infect Dis Suppl 1997; 104: 34–36.

11. Hahn DL, Golubjatnikov R. Asthma and chlamydial infection: a case series. J Fam Pract 1994; 38: 589–595.

12. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (Strain TWAR) infection with wheezing, asthmatic bronchitis and adult-onset asthma. JAMA 1991; 266: 225–230.

13. Brandén E, Koyi H, Gnarpe J et al. Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. Respir Med 2005; 99: 20–26.

14. Miyashita N, Kubota Y, Nakajima M et al. Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol 1998; 80: 405–409.

15. Allegra L, Blasi F, Centanni S et al. Acute exacerbations of asthma in adults: Role of Chlamydia pneumoniae infection. Eur Respir J 1994; 7: 2165–2168.

16. Zaitsu M. The development of asthma in wheezing infants with Chlamydia pneumoniae infection. J Asthma 2007; 44: 565–568.

17. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005; 14: 773–778.

18. Guglielminotti J, Lellouche N, Maury E et al. Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection. Clin Infect Dis 2000; 30: 209–210.

19. Anton E, Otegui A, Alonso A. Meningoencephalitis and Chlamydia pneumoniae infection. Eur J Neurol 2000; 7: 586.

20. Korman TM, Turnidge JD, Grayson ML. Neurological complications of chlamydial infection: Case report and review. Clin Inf Dis 1997; 25: 847–851.

21. Sriram S, Stratton Ch, Yao S et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6–14.

22. Stratton CW, Wheldon DB. Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumoniae. Trends Microbiol 2006; 14: 474–479.

23. Hammerschlag MR, Zheng K, Fengmin L et al. Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? J Clin Microbiol 2000; 38: 4274–4276.

24. Bagos PG, Nikolopoulos G, Ioannidis A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta‑analysis. Mult Scler 2006; 12: 397–411.

25. Hammerschlag MR, Gaydos CHA. Infectious causes of multiple sclerosis. C pneumoniae and MS: fact or fiction. Lancet Neurol 2006; 5: 892–893.

26. Gdoura R, Pereyre S, Frikha I et al. Culture-negative endocarditis due to Chlamydia pneumoniae. J Clin Microbiol 2002; 40: 718–720.

27. Gnarpe H, Gnarpe J, Gastrin B et al. Chlamydia pneumoniae and myocarditis. Scand J Infect Dis Suppl 1997; 104: 50–52.

28. Walder G, Gritsch W, Wiedermann ChJ et al. Co-infection with two Chlamydophila species in a case of fulminant myocarditis. Crit Care Med 2007; 35: 623–626.

29. Robinson-Taylor D, Thomas BJ. Chlamydia pneumoniae in atherosclerotic tissue. J Inf Dis 2000; 181 (Suppl 3): 437–440.

30. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as en emerging risk factor in cardiovascular disease. JAMA 2002; 288: 2724–2731.

31. Siscovick DS, Schwartz SM, Corey L et al. Chlamydia pneumoniae, herpes simplex virus type 1, and Cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults. Circulation 2000; 102: 2335–2340.

32. Strachan DP, Carrington D, Mendall M et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. BMJ 1999; 318: 1035–1040.

33. Roivainen M, Viik-Kajander M, Palosuo T et al. Infections, inflammation and the risk of coronary heart disease. Circulation 2000; 101: 252–257.

34. Danesh J, Whincup P, Walker M et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta‑analysis. BMJ 2000; 321: 208–213.

35. Wald NJ, Law MR, Morris JK et al. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000; 321: 204–207.

36. Haim M, Tanne D, Battler A et al. Chlamydia pneumoniae and future risk in patients with coronary heart disease. Int J Cardiol 2004; 93: 25–30.

37. Westerhout CM, Gnarpe J, Chang WC et al. No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. Am Heart J 2007; 154: 306–312.

38. Cannon CHP, Braunwald E, Carolyn H et al. Antibiotic treatment of chlamydia pneumoniea after acute coronary syndrome. N Engl J Med 2005; 352: 1646–1654.

39. Danesh J. Antibiotics in the prevention of heart attacks. The Lancet 2005; 365: 365–368.

40. Kuppuswamy VC, Gupta S. Antibiotic therapy for coronary heart disease: The myth and reality. Timely Top Med Cardiovasc Dis 2006; 10: E2.

41. Medková Z, Kalousek I, Jarčuška P. Chlamydiové infekce. Praha: Triton 2001, 73–106.